6月27日盘后,信达生物(01801.HK)公告,GCG/GLP-1双受体激动减重药物信尔美(玛仕度肽注射液)获中国国家药品监督管理局批准上市,适用于成人肥胖或超重患者的长期体重控制。公告显示,信尔美是全球首个且唯一上市的GCG/GLP-1双受体激动减重药物,能够增加减重效果并降低内脏脂肪含量。其III期注册临床研究结果显示,在48周时,信尔美4mg和6mg组受试者体重相较基线下降≥5%的比例分别...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.